542 related articles for article (PubMed ID: 30325540)
1. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
Lapitz A; Azkargorta M; Milkiewicz P; Olaizola P; Zhuravleva E; Grimsrud MM; Schramm C; Arbelaiz A; O'Rourke CJ; La Casta A; Milkiewicz M; Pastor T; Vesterhus M; Jimenez-Agüero R; Dill MT; Lamarca A; Valle JW; Macias RIR; Izquierdo-Sanchez L; Pérez Castaño Y; Caballero-Camino FJ; Riaño I; Krawczyk M; Ibarra C; Bustamante J; Nova-Camacho LM; Falcon-Perez JM; Elortza F; Perugorria MJ; Andersen JB; Bujanda L; Karlsen TH; Folseraas T; Rodrigues PM; Banales JM
J Hepatol; 2023 Jul; 79(1):93-108. PubMed ID: 36868481
[TBL] [Abstract][Full Text] [Related]
3. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
4. Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.
Ochoa-Rios S; Blaschke CRK; Wang M; Peterson KD; DelaCourt A; Grauzam SE; Lewin D; Angel P; Roberts LR; Drake R; Mehta AS
Cancer Res Commun; 2023 Mar; 3(3):383-394. PubMed ID: 36890858
[TBL] [Abstract][Full Text] [Related]
5. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
[TBL] [Abstract][Full Text] [Related]
6. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
Arbelaiz A; Azkargorta M; Krawczyk M; Santos-Laso A; Lapitz A; Perugorria MJ; Erice O; Gonzalez E; Jimenez-Agüero R; Lacasta A; Ibarra C; Sanchez-Campos A; Jimeno JP; Lammert F; Milkiewicz P; Marzioni M; Macias RIR; Marin JJG; Patel T; Gores GJ; Martinez I; Elortza F; Falcon-Perez JM; Bujanda L; Banales JM
Hepatology; 2017 Oct; 66(4):1125-1143. PubMed ID: 28555885
[TBL] [Abstract][Full Text] [Related]
7. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis.
Köhler B; Bes M; Chan HL; Esteban JI; Piratvisuth T; Sukeepaisarnjaroen W; Tanwandee T; Thongsawat S; Mang A; Morgenstern D; Swiatek-de Lange M; Dayyani F
Int J Biol Markers; 2024 Jun; 39(2):107-117. PubMed ID: 38549363
[TBL] [Abstract][Full Text] [Related]
8. Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
Chen L; Zeng F; Yao L; Fang T; Liao M; Long J; Xiao L; Deng G
Cancer Med; 2020 Feb; 9(4):1451-1461. PubMed ID: 31903730
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
Julich-Haertel H; Urban SK; Krawczyk M; Willms A; Jankowski K; Patkowski W; Kruk B; Krasnodębski M; Ligocka J; Schwab R; Richardsen I; Schaaf S; Klein A; Gehlert S; Sänger H; Casper M; Banales JM; Schuppan D; Milkiewicz P; Lammert F; Krawczyk M; Lukacs-Kornek V; Kornek M
J Hepatol; 2017 Aug; 67(2):282-292. PubMed ID: 28267620
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
Björnsson E; Kilander A; Olsson R
Liver; 1999 Dec; 19(6):501-8. PubMed ID: 10661684
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
12. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
Bernuzzi F; Marabita F; Lleo A; Carbone M; Mirolo M; Marzioni M; Alpini G; Alvaro D; Boberg KM; Locati M; Torzilli G; Rimassa L; Piscaglia F; He XS; Bowlus CL; Yang GX; Gershwin ME; Invernizzi P
Clin Exp Immunol; 2016 Jul; 185(1):61-71. PubMed ID: 26864161
[TBL] [Abstract][Full Text] [Related]
13. Characteristic Features of Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis.
Ishii Y; Sasaki T; Serikawa M; Kobayashi K; Kamigaki M; Minami T; Okazaki A; Yukutake M; Ishigaki T; Kosaka K; Mouri T; Yoshimi S; Chayama K
Hepatogastroenterology; 2014 May; 61(131):567-73. PubMed ID: 26176037
[TBL] [Abstract][Full Text] [Related]
14. Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma.
Kongtawelert P; Tangkijvanich P; Ong-Chai S; Poovorawan Y
World J Gastroenterol; 2003 Oct; 9(10):2178-81. PubMed ID: 14562373
[TBL] [Abstract][Full Text] [Related]
15. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study.
Navaneethan U; Parsi MA; Lourdusamy V; Bhatt A; Gutierrez NG; Grove D; Sanaka MR; Hammel JP; Stevens T; Vargo JJ; Dweik RA
Gastrointest Endosc; 2015 Apr; 81(4):943-9.e1. PubMed ID: 25500329
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level.
Kashihara T; Ohki A; Kobayashi T; Sato T; Nishizawa H; Ogawa K; Tako H; Kawakami F; Tsuji M; Tamaoka K
J Gastroenterol; 1998 Jun; 33(3):447-53. PubMed ID: 9658330
[TBL] [Abstract][Full Text] [Related]
17. The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.
Kuzu UB; Ödemiş B; Suna N; Yıldız H; Parlak E; Dişibeyaz S; Torun S; Akpınar MY; Coşkun O; Turhan N; Yüksel M; Kayaçetin E
J Gastrointest Cancer; 2016 Mar; 47(1):8-14. PubMed ID: 26537791
[TBL] [Abstract][Full Text] [Related]
18. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
19. Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma.
Fujimoto K; Kawaguchi T; Nakashima O; Ono J; Ohta S; Kawaguchi A; Tonan T; Ohshima K; Yano H; Hayabuchi N; Izuhara K; Sata M
Oncol Rep; 2011 May; 25(5):1211-6. PubMed ID: 21347516
[TBL] [Abstract][Full Text] [Related]
20. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
Hultcrantz R; Olsson R; Danielsson A; Järnerot G; Lööf L; Ryden BO; Wahren B; Broomé U
J Hepatol; 1999 Apr; 30(4):669-73. PubMed ID: 10207809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
